Harmony Biosciences Holdings, Inc. (HRMY) Stock Price & Analysis

Harmony Biosciences Holdings, Inc. (HRMY) closed at USD 38.5 on Wednesday, October 28, 2026, up 1.45% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 37.95; the Oct 28, 2026 session ranged USD 37.28–38.53 on volume of 1,002,679 shares. Market capitalization is $2.24B, with a 52-week range of USD 25.9–43.49 (NGM). Source: Nexqual, retrieved October 29, 2026 at 06:59 UTC.

Also available as compact Markdown for AI agents: nexqual.com/HRMY.md

Key facts (HRMY)

• Last four reported quarters (through Jun 30, 2026): revenue $960M, net income $181M (18.9% margin) (SEC filings).
• Valuation: P/E 12.4x (avg 14.2x at the last 3 fiscal year-ends), net cash $514M.
• Insider open-market sales, last ~7 months: 2 Form 4 filings, $3.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.33 on a 1–5 scale) (12 analysts), mean target USD 48.25 (range 30–70).
• Total return with dividends: 1Y +31.3% vs S&P 500 +13.6%; 5Y -7.2% vs S&P 500 +79.8%.
• Next earnings: 2026-11-04, EPS estimate USD 1.47, revenue estimate $273M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HRMY)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (HRMY)

P/E 12.4x · P/S 2.3x · EV/Sales 1.8x · P/B 2.2x · Earnings yield 8.08% · Net cash $514M · EV $1.73B

P/E at fiscal year-ends: Dec 2025 13.8x, Dec 2024 13.7x, Dec 2023 15.1x.

Insider sales (SEC Form 4, open-market, last ~7 months) (HRMY)

2 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (HRMY)

Consensus Buy (mean 2.33 on a 1–5 scale), 12 analysts; mean target USD 48.25 (low 30, high 70).

Rating changes, last 120 days:

Total return (dividends reinvested) (HRMY)

HRMY earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

HRMY recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

HRMY suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

HRMY customer concentration

In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (38%, 25%) of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name them.

HRMY company outlook (results filed Aug 4, 2026)

• “Guidance of $1. 0 Billion to $1.04 Billion Phase 1 SAD Data for BP-205 Demonstrate Favorable PK and Safety/Tolerability Profiles ;”
• “Phase 1 MAD Data Expected in Q4 2026 BP-205 IND Open in US;”
• “Data Expected Early 2027 Initiating Phase 2 Trials for BP-205 in Mid-2027 to Evaluate Multiple CNS Indications Pitolisant GR NDA Accepted in July;”

Quoted word-for-word from the SEC 8-K results press release.

HRMY analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 06:59 UTC)

Technical Analysis (HRMY)

Nexqual's technical model rates HRMY "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 06:59 UTC.

Analyst Ratings (HRMY)

Wall Street analysts rate HRMY "Buy" based on 12 analysts, with a mean price target of USD 48.25 (range USD 30–70), per Nexqual as of October 29, 2026 at 06:59 UTC.

Earnings (HRMY)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 06:59 UTC.

Financials & Fundamentals (HRMY)

Source: Nexqual, October 29, 2026 at 06:59 UTC.

Financial Health Score (HRMY)

Nexqual rates Harmony Biosciences Holdings, Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 06:59 UTC.

Ownership (HRMY)

Source: Nexqual, October 29, 2026 at 06:59 UTC.

Leadership (HRMY)

Harmony Biosciences Holdings, Inc. is led by Jeffrey M. Dayno, President, CEO & Director, per Nexqual as of October 29, 2026 at 06:59 UTC.

Major Backers & Investors (HRMY)

Notable institutional backers of Harmony Biosciences Holdings, Inc. include FMR, LLC, American Century Companies Inc, LSV Asset Management, according to Nexqual as of October 29, 2026 at 06:59 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 06:59 UTC.

From Harmony Biosciences Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• There are multiple FDA approved therapies for the treatment of DS, LGS or both DS and LGS including, but not limited to, products from Jazz Pharmaceuticals for the treatment of DS and LGS, UCB for the treatment of DS and LGS, Biocodex for the treatment of DS, Eisai Co., Ltd. for the treatment of LGS, Janssen for the treatment of LGS, GlaxoSmithKline for the treatment of LGS, and Assertio Holdings for the treatment of LGS.
• Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.
• Changes in either the patent laws or their interpretation in the United States, or in other foreign jurisdictions where we have sought patent protection, may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property.
• In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in enforcing patent claims that cover our technology, inventions and improvements.

Partnerships

• In July 2022, we entered into a License and Commercialization Agreement with Bioprojet (the "2022 LCA") whereby we obtained exclusive rights to manufacture, develop and commercialize one or more next generation pitolisant based products in the United States and Latin America.
• In July 2022, we entered into the 2022 LCA with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties (see "Strategic Agreements" below).

Legal & Regulatory Risks (Item 1A, quoted)

• The regulatory approval process of the FDA is costly, lengthy and inherently unpredictable, and our business may be substantially harmed if we experience insufficient results in the course of our clinical development or are ultimately unable to obtain regulatory approval for any of our ongoing development programs in other potential indications.
• Any of these events could prevent us from achieving or maintaining market acceptance of pitolisant and could significantly harm our business, results of operations, financial condition and prospects.
• The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired.
• We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:59 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt